Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Extending the time between dose increases may benefit patients with persistent symptoms
Transaction Solutions Global Claims Study Better Decisions Across Interconnected Risk and People Issues
MT-II is associated with reported cases of benign nevi modification (darkening) and, more rarely, with dermatological concerns (warranting dermato-oncological surveillance in at-risk subjects)
Expected Recovery Timeline Setting appropriate expectations for recovery timelines helps optimize protocol adherence and prevents premature disappointment or unnecessary protocol modifications
It would be important to tease that out
US$ 28.95
US$ 22.71
US$ 28.13
